DAL vs RXRX · P/E 12, rev $61.64B vs rev $58.8M
Delta Air Lines Inc (DAL) versus Recursion Pharmaceuticals Inc (RXRX) — a side-by-side from cached financials, not a winner call.
Delta Air Lines Inc (DAL) is a airlines company listed on US. It is led by Ed Bastian.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
Latest reported DAL revenue for 2024-12-31 was $61.64B. Net income was $3.46B. Revenue was up 6.2% from 2023-12-31 to 2024-12-31. DAL currently screens at market cap $52.18B and trailing P/E 11.6.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
DAL currently screens at market cap $52.18B and trailing P/E 11.6. RXRX currently screens at market cap $1.75B.
Not investment advice. Open the DAL and RXRX stock pages for the full models.
Not investment advice.